Climate Change Data

Bioventix PLC

Climate Impact & Sustainability Data (2021, 2022)

Reporting Period: 2021

Environmental Metrics

ESG Focus Areas

  • Social
  • Environmental
  • Governance

Environmental Achievements

  • Completed significant refurbishment of facilities ensuring improved water utilisation and energy efficiency.
  • Encouraged staff to reduce wastage, optimize use of resources, and switch off electrical equipment when not in use.
  • Reduced business travel through greater adoption of technology for virtual meetings.

Social Achievements

  • Maintained regular communication and dialogue with stakeholders.
  • Applied fair employment practices and complied with all employment legislation.
  • Invested in healthy and safe workplaces and implemented various employee policies (Equal Opportunities, Anti-harassment, Health and Safety, GDPR, Flexible Working, Parental Leave, etc.).
  • Supported staff working from home during the COVID-19 pandemic.
  • Maintained open communication with staff regarding company strategy and performance.

Governance Achievements

  • Adopted the QCA Corporate Governance Code.
  • Undertook an annual review of the corporate governance framework.
  • Established an Audit Committee, a Remuneration Committee, and a Nominations Committee.
  • Implemented a comprehensive suite of policies covering conduct and ethics (anti-bribery, modern slavery, safeguarding).

Climate Goals & Targets

Medium-term Goals:
  • Continued roll-out of high sensitivity troponin assays.
Short-term Goals:
  • Explore production systems (such as E.coli) to improve production techniques for biotin blockers and THC/cannabis antibodies.

Environmental Challenges

  • Adverse impact of foreign exchange movements.
  • Increased charge in respect of share options issued in previous years.
  • Flatter downstream market for vitamin D testing and pandemic effects.
  • Regulatory approvals for domestic Chinese customers have considerable lead times.
  • Development of antibody technology companies in China represents a longer-term challenge.
  • Relative global geopolitical stability will be important for continued trade.
  • COVID-19 pandemic adversely affected routine diagnostic pathways and patient willingness to seek healthcare.
  • Supply chain issues caused by various factors (reagents, plastics, filters).
  • Some lost opportunities for SMA technology due to competition from rabbit monoclonal and synthetic antibody technologies.
Mitigation Strategies
  • Careful stock planning and sourcing alternatives to manage supply chain issues.
  • Continued investment in research projects.
  • Maintaining a cash balance of approximately £5 million to facilitate operational and strategic agility.
  • Exploring production systems (such as E.coli) to improve production techniques and commercial feasibility.
  • Working with a UK industrial site to conduct a field trial of a pyrene exposure device and app.

Supply Chain Management

Responsible Procurement
  • Careful stock planning and sourcing alternatives.

Climate-Related Risks & Opportunities

Sustainable Products & Innovation

  • Pyrene exposure device and app

Reporting Period: 2022

Environmental Metrics

ESG Focus Areas

  • Environmental
  • Social
  • Governance

Environmental Achievements

  • Converted one process to use bioreactors, reducing plastic flask usage.
  • Implemented genetic engineering techniques resulting in a four-fold increase in the yield of one antibody production.
  • Using SMAs made in vitro to replace mass immunization of sheep for T4 (thyroxine) antibody, reducing animal usage.
  • Significant refurbishment of facilities improving water usage and energy efficiency.

Social Achievements

  • Maintained regular communication and dialogue with stakeholders.
  • Applied fair employment practices and complied with all legislation and requirements regarding employment.
  • Invested in healthy and safe workplaces.
  • Supported new parents in their desire to return to work, resulting in four part-time employees.

Governance Achievements

  • Followed the guidelines of the Quoted Companies Alliance.
  • Continued efforts to increase Board diversity.
  • Operates a Quality Management System based on the principles of ISO 9001:2015 and ISO 13485:2016.

Climate Goals & Targets

Long-term Goals:
  • Extend success to dementia diagnostics.
Short-term Goals:
  • Continued commercial development of new troponin assays.

Environmental Challenges

  • Supply chain issues relating to plastics and chemical reagents.
  • Turmoil in the energy market, predicting power outages.
  • Limited candidate availability compromising progress in Board diversity.
Mitigation Strategies
  • Expertly managed supply chain issues by procurement team.
  • Planned to use diesel generator and reserve fuel supplies to minimize power outage disruption.
  • Continued efforts to increase Board diversity.

Supply Chain Management

Climate-Related Risks & Opportunities

Reporting Standards

Frameworks Used: Quoted Companies Alliance Corporate Governance Code

Certifications: ISO 9001:2015, ISO 13485:2016

Sustainable Products & Innovation

  • Pyrene lateral flow system for industrial pollution biomonitoring
  • Assays for benzene and isocyanates